Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb13676 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Non-CLL B Cell Malignancies (Group NHL) Part A | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| CLL/SLL (Group CLL) Part A | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part B | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| CLL/SLL (Group CLL) Part B | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion | EXPERIMENTAL | XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Name | Type | Description |
|---|---|---|
| XmAb13676 | BIOLOGICAL | Biological |
Inclusion Criteria: * Able to provide written informed consent * Diagnosis of either Non-CLL B cell malignancy * Ineligible for or have exhausted standard therapeutic options and have relapsed or refractory disease * ECOG performance status 0-2 * Fertile patients must agree to use highly effective ...
XmAb13676 is an investigational monoclonal antibody being studied for the treatment of B-cell Non-Hodgkin's Lymphoma. It is also being evaluated in patients with Chronic Lymphocytic Leukemia. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
XmAb13676 targets CD20, a protein expressed on the surface of B-cells. By binding to CD20, the antibody is designed to engage immune effector cells to attack and eliminate CD20-expressing malignant B-cells, which are characteristic of B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.
XmAb13676 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. Xencor is conducting clinical trials to evaluate the safety and tolerability of this investigational antibody in patients with CD20-expressing hematologic malignancies.
XmAb13676 is in Phase 1 clinical development. A Phase 1 study has been completed to evaluate its safety and tolerability in patients with CD20-expressing hematologic malignancies. The drug remains investigational and has not received FDA approval.
XmAb13676 has been studied in a Phase 1 clinical trial with the identifier NCT02924402. This completed study enrolled 154 participants and evaluated the safety and tolerability of the drug in patients with B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia across the United States, France, South Korea, and the United Kingdom.
Yes, XmAb13676 is also known as plamotamab. The clinical trial NCT02924402, which evaluated the safety and tolerability of XmAb13676, refers to the drug as plamotamab in its title. Both names refer to the same investigational monoclonal antibody developed by Xencor.